

## For Immediate Release

Contact: Kim Golden  
Respironics, Inc.  
OEM Product Manager  
203-697-6454

### Respironics Introduces LoFlo™ Sidestream CO<sub>2</sub> Sensor for Use with Philips Medical Systems Patient Monitors

Murrysville, PA, April, 2006 – Respironics, Inc. (NASDAQ/NMS Symbol: RESP) is pleased to announce a new OEM Agreement with Philips Medical Systems for our new LoFlo sidestream CO<sub>2</sub> technology. Philips Medical Systems will now offer the new LoFlo™ Sidestream CO<sub>2</sub> sensor and accessories for use with their IntelliVue family of patient monitors. Philips plans to begin shipment of this product in April, 2006.

The LoFlo sensor is the ideal low sampling rate sidestream capnography solution for monitoring adult, pediatric and neonatal patients. It measures End-Tidal Carbon Dioxide (ETCO<sub>2</sub>) and respiration rate at a new low sample rate of 50 ml/minute. The LoFlo Sensor is built using the same electronics as its sister product, the CAPNOSTAT® 5 mainstream sensor, and provides flexible “Plug & Play” interchangeability between the two technologies. This allows Philips’ customers the option to easily mix and match mainstream and sidestream technologies based on their specific patient requirements.



The LoFlo Sensor’s uniquely designed sample cell is permanently attached to the disposable sampling accessories, rather than housed inside of the module. This eliminates the potential for contamination due to excessive water or patient secretions. The patented design of the sample cell enables continuous protection of the measurement system and provides maximum reliability, reduced maintenance costs and maximized monitor utilization. In addition, the LoFlo accessories have an improved filtering system which provides for up to 120 hours of continuous monitoring minimizing overall cost of ownership for the customer.

#### CORPORATE SERVICES

1010 Murry Ridge Lane ~ Murrysville, PA 15668  
T 724-387-5200 F 724-387-5010



According to Philip Nuzzo, Vice President of OEM, Respironics Critical Care, “The addition of LoFlo Sidestream technology now provides customers with the most flexible CO<sub>2</sub> solution available. We are excited that Philips has chosen to extend our relationship by adding the LoFlo technology as a complement to their existing CAPNOSTAT<sup>®</sup> 5 mainstream solution. We look forward to working with Philips to extend our reach in the sidestream market space.”

### **About Respironics, Inc.**

Respironics is a leading developer, manufacturer and distributor of innovative products and programs that serve the global sleep and respiratory markets. Focusing on emerging market needs, the Company is committed to providing valued solutions to help improve outcomes for patients, clinicians and health care providers. Respironics markets its products in 131 countries and employs over 4,300 associates worldwide. Further information can be found on the Company’s Web site: [www.respironics.com](http://www.respironics.com).

# # #

This document contains forward-looking statements, including statements relating to, among other things, developments in the healthcare industry; the success of the Company's marketing, sales, and promotion programs; future sales and acceptance of the Company's products and programs; the timing and success of new product introductions; new product development; anticipated cost savings; FDA and other regulatory requirements and enforcement actions; future results from acquisitions; acquisition integration; growth rates in foreign markets; regulations and other factors affecting operations and sales outside the United States (including potential future effects of the change in sovereignty of Hong Kong); foreign currency fluctuations; customer consolidation and concentration; increasing price competition and other competitive factors in the sale of products; interest rate fluctuations; expiration of intellectual property rights; intellectual property and related litigation; other litigation; future levels of earnings and revenues; and third party reimbursement, all of which are subject to change. Actual results may differ materially from those described in any forward-looking statements. Additional information on potential factors that could affect the Company's financial results are included in the reports filed with the SEC, including the reports on Form 10-K, 10-Q and 8-K.

© 2006 Respironics, Inc. and its affiliates

**CORPORATE SERVICES**  
1010 Murry Ridge Lane ~ Murrysville, PA 15668  
T 724-387-5200 F 724-387-5010